RE:RE:As THRM is alone in this field and has a functional test it Once again we have someone who jumps on this board touting their understanding of biology, business, long term requirements ....and the markets.
STOP WITH THE BS!
First of all, the need is enormous ....so there will not be one player. The company you have alluded to can't even meet the US requirements. That's like saying once Phizer released their vaccine all the other players should have just walked away.
Second, the testing is about to begin, won't take long and then you can offer an opinion about the interest by investors with deep wallets. Until then there was no reason for BIG business to get involved or for it to be fast tracked .....there was no test yet. In fact big pharma had walked away from saliva tests early in the pandemic ....read the NEWS!
Finally, of course the technology is from another firm. Thrm (Orpheus) did the biology ....found suitable, identifiable markers on the covid-19 virus.. Then you required a company that had the technology to be able to detect the presence of those markers (NanoComposix). Then you had to find a means to meet the government requirements for specificity and sensitivity (most recent NR). Now you test, collate results and apply for governmental review of your device (CoviSafe).
In the meantime you have a former exec from one of the largest medical manufacturing companies in Canada with facilities all over the world co-ordinating commercialzationnand production.
Like I said, cut the BS. If you're going post do your HOMEWORK!
Cheers!
TheeRook wrote: This will not attract Big players, the technology behind it is from a contract firm who is developing the test fro THRM.
. If it was even remotely any good the US Gov would have given grants for the test to be fast tracked thtough POCTRM , NiH and RADx. Like the at home Ellume Test
This project has been funded in part by the NIH RADx initiative with US federal funds from the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Biomedical Advanced Research and Development Authority, Department of Health and Human Services, under Contract No. 75N92020C00034. Ellume acknowledges the great assistance of the NIH in making practical Covid19 rapid testing an effective reality.
FDA AUTHORIZES ELLUME COVID-19 HOME TEST AS FIRST OVER-THE-COUNTER FULLY AT-HOME DIAGNOSTIC TEST
Proven performance in adults and children, with and without symptoms
Highlights
FDA grants Emergency Use Authorization for Ellume COVID-19 Home Test for non-prescription home use in symptomatic and asymptomatic individuals
The test demonstrated 96% accuracy in a multi-site US clinical study of both adults and children 2 years and above
Ellume is ramping up manufacture, with production on track for over 100,000 tests per day in January 2021
sylvain_007 wrote: will attract the attention of big players.
First of all, approvals are needed, first from Health Canada and then from the FDA, afterwards THRM will attract the attention of everyone. People who have paid $1 per share will recover their bet and those who have paid less will recover their bet as well. But we have to get those approvals before we think everything will be okay. Since this is the only test people will take, chances are that the approvals will not take too long to answer.